P
Precirix
Camelid-derived radiopharmaceuticals for targeted cancer therapy
About Precirix
Precirix is a pioneering biotechnology company focused on transforming the field of cancer treatment through innovative solutions. Established with the aim of addressing significant challenges in oncology, Precirix is dedicated to developing advanced diagnostic and therapeutic tools that enhance the precision and effectiveness of cancer care.
Read full description
The company's flagship technology centers on its proprietary radio-labeled imaging agents, which are designed to improve the accuracy of cancer detection and treatment planning. By leveraging cutting-edge radiopharmaceuticals and advanced imaging techniques, Precirix aims to provide clinicians with more precise diagnostic information, leading to better-informed treatment decisions and improved patient outcomes.
In addition to its diagnostic capabilities, Precirix is also at the forefront of developing targeted therapies that combine imaging and treatment in a single approach. This integrated strategy allows for more personalized and effective treatment options, tailored to the specific characteristics of each patient’s cancer.
Precise and timely cancer treatment is crucial for improving survival rates and quality of life. Precirix’s innovative approach promises to enhance the overall efficacy of cancer management by offering solutions that address both the diagnostic and therapeutic needs of oncology.
With a commitment to advancing cancer care through technology, Precirix is poised to make significant contributions to the field, ultimately aiming to improve patient outcomes and revolutionize the approach to cancer treatment.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Jette, Belgium
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 61.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Health Diagnostics, Spinout, Biotech and Pharma, Radioisotope Therapeutics, Hard Tech, Radiopharmaceuticals, DT and LS, science-based
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Mar 2022 | $88M | $352M | BioMedVC · HealthCap · Pontifax Funds · Inkef | ↗ |
| SERIES AOther financing | Nov 2018 | $42M | $168M | HealthCap · Novo Seeds · Gimv · BioMedVC | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Precirix is 40 monthly website visits, down 98.1% over the last three months. Precirix's team declined 72.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Gimv
V-Bio Ventures
HealthCap
Novo Seeds
BioMedVC
Pontifax Funds
Inkef
Forbion Capital Partners
Jeito Capital
Novo Holdings
Other known investors1 additional known investor
Vrije Universiteit Brussel
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Precirix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Precirix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.